Skip to content

U-100 unit conversion

TUDCA (Tauroursodeoxycholic Acid) calculator

Convert mass and volume to U-100 units. No dose is selected.

These are example numbers so you can see the math. Try yours. Change them to match the vial in your hand.

0.2U-100 units · 0.002 mL

1250 mcg per unit · 125000 mcg/mL

That draw is under 5 units, so the barrel is easy to misread. Check your inputs and measuring equipment with a qualified professional. The page does not select a dose or preparation.

How the calculator works, sources and review dates

TUDCA (Tauroursodeoxycholic Acid) math uses the listed vial sizes on this card and the liquid you type. Concentration in mcg per mL is vial milligrams times 1000, divided by milliliters. A U-100 syringe has 100 marks per milliliter, so each unit is that concentration divided by 100. Example numbers so you can see the math: a 250 mg listing plus 2 mL of liquid. Change any number and the units change. Try the numbers. A research-market vial is not the same material used in a trial.

Editorial review 2026-10-09. source-curated; clinician review pending.

Units chart for listed TUDCA (Tauroursodeoxycholic Acid) sizes

U-100 math for listed TUDCA (Tauroursodeoxycholic Acid) sizes. Each cell is micrograms per syringe mark if you add that much liquid. The table does the same math as the calculator. It does not pick an amount for you.

Micrograms per U-100 unit (100 marks / mL)
Listed vial1 mL liquid2 mL liquid3 mL liquid
250 mg25001250833.3
500 mg500025001666.7

What is TUDCA (Tauroursodeoxycholic Acid)?

Other names in the library: tauroursodeoxycholic acid, TUDCA - 250mg, TUDCA - 500mg, TUDCA. Evidence describes the named substance, not a quality certification or equivalence assessment of commercial stock. Listed sizes: 250 mg, 500 mg. A seller title is a listing. It does not prove the vial matches a paper.

What the evidence says

For each trial, check who or what was studied, which preparation was used and what the findings support before comparing it with personal reports about individual experiences or seller listings that describe a product but don’t establish that it works.

Human trial

TUDCA primary study · PMID 25664595

34 ALS patients receiving riluzole in an early proof-of-principle randomized trial.

Reported findings. In the 34-person ALS pilot, 87% with TUDCA versus 43% with placebo met the study-defined responder measure: at least 15% improvement in ALSFRS-R decline slope relative to their own lead-in phase (P=.021). Functional progression was slower; this measure does not mean recovery or a population success rate.

Nonresponse. Not every participant met this slope-based responder definition. The later 336-person phase3 trial did not confirm benefit, reported separately.

Harms. No between-group difference in adverse events was reported in the pilot; small samples cannot establish uncommon or long-term safety.

Limits. A small early disease-specific study is not proof of liver detoxification or a confirmed current ALS treatment. Later trial outcomes must be checked before any treatment conclusion. 2017 corrigendum changes author affiliation only; it does not alter study outcomes. Later phase3 negative findings are recorded separately.

Preparation: Source preparation; commercial equivalence unverified. Route: oral

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Human trial

TUDCA-ALS consortium: Phase 3 top-line results (2024)

336 randomized participants with ALS across 25 European sites; consortium announcement March 27, 2024.

Reported findings. No positive effect established on the stated primary outcome.

Nonresponse. The Phase 3 TUDCA-ALS trial did not show significant benefit on its primary functional endpoint or secondary survival and biomarker endpoints.

Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.

Limits. Top-line consortium report; pandemic recruitment and attrition limited precision. EU-funded research, not a commercial-product equivalence study.

Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Identity context

Corrigendum.

Publication correction.

Reported findings. The corrigendum changes A. Albanese’s institutional affiliation.

Nonresponse. No outcome, participant-count or statistical correction in this notice.

Harms. Not a clinical safety study.

Limits. Administrative correction must not be represented as evidence that the outcome result was wrong.

Preparation: Publication provenance; not a treatment preparation. Route: not applicable

Read original source ↗

Editorial review 2026-10-09. Clinician review pending.

Regulatory status, dated 2026-10-09

FDA product approval

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Compounding

not established. Legal compounding eligibility is not established here. Sale or a supplement label does not establish eligibility.

Research

investigational. 34 ALS patients receiving riluzole in an early proof-of-principle randomized trial.

Sport

unknown. Not individually verified against current sport rules. Check the exact ingredients with your sport authority.

How long it lasts, how you store it, listed sizes

This entry doesn’t give a duration in hours. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule.

Half-life on file: no single hour value. No verified human estimate for this exact preparation is supplied. A half-life is not a treatment schedule. Follow the label on the vial you hold. This page does not set a throw-away date after you add water.

Risks and mix-ups already on the record

  • Human safety for this exact preparation is incompletely characterized. A lack of reported problems does not establish safety.
  • No complete contraindication list is established for this exact preparation. Review pregnancy, allergies and existing conditions with a clinician.
  • No complete interaction study for this exact preparation is verified. Ingredient combinations are not presumed compatible.

People using PepBear often log: Exact product identity, formulation, dated label and any clinician-directed observations. Record symptoms and changes alongside other medicines, sleep and activity; observations do not establish causation.

Sources

  1. TUDCA primary study · PMID 25664595 · checked 2026-10-09
  2. TUDCA-ALS consortium: Phase 3 top-line results (2024) · checked 2026-10-09

Questions people ask

Is TUDCA (Tauroursodeoxycholic Acid) FDA-approved?

not established. No approval for this exact marketed preparation or claimed wellness indication is established in this source set.

Does PepBear pick an amount of TUDCA (Tauroursodeoxycholic Acid)?

The calculator turns numbers you type into U-100 units. Trial or label amounts stay as cited facts.

How many units is a listed TUDCA (Tauroursodeoxycholic Acid) vial after you add water?

Units = (amount in mcg ÷ (vial mg × 1000 ÷ water mL)) × 100 on a U-100 syringe. Enter the three numbers. The chart shows the same math for each listed vial size and 1, 2 or 3 mL of liquid.

Why flag amounts under 5 units?

A U-100 barrel is easy to misread below about 5 marks. That is a measuring warning. The page does not tell you to take more.

Related cards

Discuss the evidence and unresolved identity or safety questions with a licensed clinician. This entry provides no treatment instructions. Not medical advice. PepBear does not pick a dose, a cycle, or a seller.